全球多癌種早期檢測市場規模、佔有率、趨勢及成長分析報告（2026-2034）

預計到 2034 年，多種癌症早期檢測的市場規模將從 2025 年的 24.9 億美元成長至 87.9 億美元，2026 年至 2034 年的複合年成長率為 15.07%。

隨著醫療系統日益重視癌症的早期檢測，全球多癌種早期檢測市場正經歷強勁成長。多癌種早期檢測旨在透過單次篩檢檢測多種癌症的徵兆。這些技術通常依賴先進的基因組分析和生物標記分析來識別血液樣本中與癌症相關的變化。早期檢測能夠顯著改善癌症患者的治療效果和存活率。

分子診斷和次世代定序技術的進步正在推動該市場的創新。研究人員和生技公司正在開發高靈敏度的檢測方法，能夠檢測血液中微量的癌症相關遺傳物質。醫療機構正在擴大早期篩檢計畫的部署，以改善人群健康並減輕晚期癌症的治療負擔。

隨著精準醫療和個人化醫療的進步，市場預計未來將持續成長。大規模臨床試驗和監管核准將加速多篩檢篩檢檢測的廣泛應用。隨著預防醫學意識的不斷提高，多癌種早期檢測技術有望成為常規篩檢計畫的重要組成部分。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球多種癌症早期檢測市場：按類型分類

• 市場分析、洞察與預測
• 基因檢測板、實驗室自建檢測及其他
• 液態生物檢體

第5章：全球多種癌症早期檢測市場：依最終用途分類

• 市場分析、洞察與預測
• 醫院
• 診斷檢查室
• 其他最終用戶

第6章：全球多種癌症早期檢測市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • AnPac Bio-Medical Science Co. Ltd
  • Burning Rock Biotech Limited
  • EarlyDiagnostics
  • Elypta AB
  • Exact Sciences Corporation
  • Freenome Holdings Inc
  • Genecast Biotechnology Co. Ltd
  • Guangzhou AnchorDx Medical Co. Ltd
  • Guardant Health Inc
  • Illumina Inc.（GRAIL Inc.）
  • Micronoma Inc
  • Oncocyte Corporation
  • Roche Holding AG（Foundation Medicine Inc.）
  • SeekIn Inc
  • Singlera Genomics Inc

The Multi Cancer Early Detection Market size is expected to reach USD 8.79 Billion in 2034 from USD 2.49 Billion (2025) growing at a CAGR of 15.07% during 2026-2034.

The global multi cancer early detection market is experiencing strong growth as healthcare systems focus on identifying cancer at its earliest stages. Multi cancer early detection tests are designed to detect signals from multiple types of cancer using a single screening test. These technologies often rely on advanced genomic and biomarker analysis to identify cancer-related changes in blood samples. Early detection significantly improves treatment outcomes and survival rates for cancer patients.

Advancements in molecular diagnostics and next-generation sequencing technologies are driving innovation in this market. Researchers and biotechnology companies are developing highly sensitive tests capable of detecting small traces of cancer-related genetic material in the bloodstream. Healthcare providers are increasingly adopting early detection screening programs to improve population health and reduce the burden of late-stage cancer treatments.

In the future, the market is expected to grow as precision medicine and personalized healthcare continue to advance. Large-scale clinical studies and regulatory approvals will help expand the availability of multi cancer screening tests. As awareness about preventive healthcare increases, multi cancer early detection technologies are likely to become an important part of routine medical screening programs.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Gene Panel, LDT, & Others
• Liquid Biopsy

By End-use

• Hospitals
• Diagnostic Laboratories
• Other End-users

COMPANIES PROFILED

• AnPac BioMedical Science Co Ltd, Burning Rock Biotech Limited, EarlyDiagnostics, Elypta AB, Exact Sciences Corporation, Freenome Holdings Inc, Genecast Biotechnology Co Ltd, Guangzhou AnchorDx Medical Co Ltd, Guardant Health Inc, Illumina Inc GRAIL Inc, Micronoma Inc, Oncocyte Corporation, Roche Holding AG Foundation Medicine Inc, SeekIn Inc, Singlera Genomics Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MULTI CANCER EARLY DETECTION MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Gene Panel, LDT, & Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Liquid Biopsy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MULTI CANCER EARLY DETECTION MARKET: BY END-USE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End-use
• 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Other End-users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MULTI CANCER EARLY DETECTION MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Type
  • 6.2.2 By End-use
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Type
  • 6.3.2 By End-use
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Type
  • 6.4.2 By End-use
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Type
  • 6.5.2 By End-use
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Type
  • 6.6.2 By End-use
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL MULTI CANCER EARLY DETECTION INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 AnPac Bio-Medical Science Co. Ltd
  • 8.2.2 Burning Rock Biotech Limited
  • 8.2.3 EarlyDiagnostics
  • 8.2.4 Elypta AB
  • 8.2.5 Exact Sciences Corporation
  • 8.2.6 Freenome Holdings Inc
  • 8.2.7 Genecast Biotechnology Co. Ltd
  • 8.2.8 Guangzhou AnchorDx Medical Co. Ltd
  • 8.2.9 Guardant Health Inc
  • 8.2.10 Illumina Inc. (GRAIL Inc.)
  • 8.2.11 Micronoma Inc
  • 8.2.12 Oncocyte Corporation
  • 8.2.13 Roche Holding AG (Foundation Medicine Inc.)
  • 8.2.14 SeekIn Inc
  • 8.2.15 Singlera Genomics Inc